OPTHEA LTD-SPON ADR (OPT)

Opthea to Present at the OIS Retina Innovation Summit at ARVO

MELBOURNE, Australia and PRINCETON, N.J., April 25, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage...

Opthea Appoints John Han, PharmD, as VP Medical Affairs

Brings extensive experience in retinal and ophthalmology diseases...

Opthea to Participate in the 23ʳᵈ Annual Needham Virtual Healthcare Conference

MELBOURNE, Australia and PRINCETON, N.J., April 04, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage...

Opthea Appoints Sujal Shah to the Board of Directors

Former CymaBay Therapeutics CEO brings extensive leadership experience to his role as a Non-Executive Director and Audit and Risk Committee Chair...

7 Growth Stocks to Buy to Outperform the Nasdaq Index

These seven high-growth stocks across various sectors have the potential to outperform the tech-heavy Nasdaq over the long-run.

Opthea to Host Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degeneration on April 3, 2024

MELBOURNE, Australia and PRINCETON, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT; “Opthea”), a clinical-stage...

Opthea to Participate in the Leerink Partners Global Biopharma Conference

MELBOURNE, Australia, March 05, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT; “Opthea”), a clinical-stage biopharmaceutical company...

Opthea Reports Half-Year Financial Results and Business Updates

Enrollment completion of sozinibercept Phase 3 program for wet AMD expected in calendar year (CY) Q2 2024 with top-line data mid-CY 2025 Expanded U.S....

Opthea Appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor

Global retina expert joins to support sozinibercept development and launch preparation...

Opthea Completes Enrollment in First Pivotal Trial with Sozinibercept

COAST trial is evaluating the superiority of sozinibercept combined with EYLEA® (aflibercept) over EYLEA alone in wet AMD Enrollment of second pivotal...

Opthea Strengthens Team with Key Clinical and Regulatory Hires

Dr. Julie Clark, SVP Clinical Development; Dr. Fang Li, SVP Regulatory Affairs, to join February 1stExperienced executives bring extensive track record in...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

It's time to dive into the biggest pre-market stock movers on Tuesday with a breakdown of all the latest news affecting shares this morning.

Opthea to receive $35M commitment and additional $50M funding (NASDAQ:OPT)

Opthea secures $85 million funding for Phase 3 clinical trials of sozinibercept through a new co-investor and existing partners Carlyle and Abingworth.

Opthea to Receive US$35M Commitment and Additional US$50M Funding

Opthea to Receive US$35M Commitment and Additional US$50M Funding

Opthea to receive remaining US$35m funding under the Development Funding Agreement (DFA) with Carlyle and its life science franchise Abingworth, as well as...

Opthea Receives A$8.8 million R&D Tax Incentive

Opthea Receives A$8.8 million R&D Tax Incentive

MELBOURNE, Australia, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel...

Opthea to Present at the FLORetina 2023 Congress

Opthea to Present at the FLORetina 2023 Congress

MELBOURNE, Australia, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel...

Opthea to Present at the Jefferies 2023 London Healthcare Conference

Opthea to Present at the Jefferies 2023 London Healthcare Conference

MELBOURNE, Australia, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel...

Opthea to Present at Eyecelerator Forum at the 2023 American Academy of Ophthalmology (AAO) Conference

Opthea to Present at Eyecelerator Forum at the 2023 American Academy of Ophthalmology (AAO) Conference

MELBOURNE, Australia, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel...

Opthea appoints U.S.-based leadership with Fred Guerard as CEO (NASDAQ:OPT)

Opthea appoints new CEO and CFO to drive the company's global presence and commercialization strategy for sozinibercept.

Opthea Appoints U.S.-Based Leadership with Fred Guerard as CEO and Peter Lang as CFO

Opthea Appoints U.S.-Based Leadership with Fred Guerard as CEO and Peter Lang as CFO

Dr. Megan Baldwin transitions to Founder, Chief Innovation Officer and remains on the Board of Directors Experienced pharmaceutical executives Dr....

Opthea to Participate at the 2023 Euretina Congress

Opthea to Participate at the 2023 Euretina Congress

MELBOURNE, Australia, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel...

Opthea to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Opthea to Present at the H.C. Wainwright 25th Annual Global Investment Conference

MELBOURNE, Australia, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing...

Opthea raises additional capital, up to $57.6M (NASDAQ:OPT)

Opthea (OPT) has accepted an additional A$10M in oversubscriptions, increasing the placement size to A$20M and the total size of the capital raising to A$90M

Opthea Successfully Completes Institutional Offer and Increases Capital Raising to A$90.0m (US$57.6 million¹)

Opthea Successfully Completes Institutional Offer and Increases Capital Raising to A$90.0m (US$57.6 million¹)

OPT has successfully completed the placement and institutional entitlement offer components of its previously announced capital raisingAs a result of...

Opthea Announces “Sozinibercept” as the Nonproprietary Drug Name for OPT-302

Opthea Announces “Sozinibercept” as the Nonproprietary Drug Name for OPT-302

MELBOURNE, Australia, July 26, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel...